Regression of mature lymphatic vessels in the cornea by photodynamic therapy

British Journal of Ophthalmology

Volumn 98, Issue 3, 2014, Pages 391-395

  Bucher, Franziska ^a   Bi, Y ^b   Gehlsen, U ^a   Hos, D ^a   Cursiefen, C ^a   Bock, F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CORNEA; NEOVASCULARISATION; TREATMENT LASERS;

ANIMALS; ANTIGENS, CD45; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 84894054962     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303887     Document Type: Article

References (33)

1. Bock F, Maruyama K, Regenfuss B, et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 2013;34: 89-124.
2. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010;184: 535-9.
3. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010;117:1300-5, e7.
4. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009;15: 1023-30.
5. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 2002;21: 405-9.
6. Cursiefen C, Bock F, Horn FK, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009;116: 1630-7.
7. Regenfuss B, Bock F, Cursiefen C. Corneal angiogenesis and lymphangiogenesis. Curr Opin Allergy Clin Immunol 2012;12: 548-54.
8. Koenig Y, Bock F, Kruse FE, et al. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea 2012;31: 887-92.
9. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000;41: 2148-53.
10. Weiss A, den Bergh H, Griffioen AW, et al. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. Biochim Biophys Acta 2012;1826: 53-70.
11. Tammela T, Saaristo A, Holopainen T, et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 2011;3:69rall.
12. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999;106: 1915-23.
13. Harding S. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation. Eye (Lond) 2001;15(Pt 3): 407-12.
14. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108: 841-52.
15. Ziemssen F, Heimann H. Evaluation of verteporfin pharmakokinetics- redefining the need of photosensitizers in ophthalmology. Expert Opin Drug Metab Toxicol 2012;8: 1023-41.
16. Yoon KC, Ahn KY, Lee SE, et al. Experimental inhibition of corneal neovascularization by photodynamic therapy with verteporfin. Curr Eye Res 2006;31: 215-24.
17. Brooks BJ, Ambati BK, Marcus DM, et al. Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol 2004; 88:840.
18. Holzer MP, Solomon KD, Vroman DT, et al. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003;44: 2954-8.
19. Bock F, Onderka J, Hos D, et al. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 2008;87: 462-70.
20. Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, et al. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 2002;43: 2127-35.
21. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48: 2545-52.
22. Chen L, Cursiefen C, Barabino S, et al. Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci 2005;46: 4536-40.
23. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. The Journal of clinical investigation 2005;115: 2363-72.
24. Bucher F, Parthasarathy A, Bergua A, et al. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol Published Online First: 20 Sep 2012. doi: 10.1111/j.1755-3768.2012.02525.x
25. Noffke AS, Jampol LM, Weinberg DV, et al. A potentially life-threatening adverse reaction to verteporfin. Arch Ophthalmol 2001;119:143.
26. Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after verteporfin therapy. Am J Ophthalmol 2005;140: 936-7.
27. Beaumont P, Lim CS, Chang A, et al. Acute severe vision decrease immediately after photodynamic therapy. Arch Ophthalmol 2004;122: 1546-7.
28. Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages after verteporfin therapy. Am J Ophthalmol 2004;137: 558-60.
29. Truong T, Altiok E, Yuen D, et al. Novel characterization of lymphatic valve formation during corneal inflammation. PLoS One 2011;6:e21918.
30. Chen L. Ocular lymphatics: state-of-the-art review. Lymphology 2009;42: 66-76.
31. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010;140: 460-76.
32. Bock F, Onderka J, Dietrich T, et al. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 2008;246: 115-9.
33. Singh N, Tiem M, Watkins R, et al. Soluble vascular endothelial growth factor receptor-3 is essential for corneal alymphaticity. Blood 2013;121: 4242-9.